DIGITAL LIFE SCIENCESShortening the gap between product innovation and effective patient outcomes
We are digital transformation enablers that bring together the science of product development and digital tools to shorten the gap of patient influence to help the industry make better products.
WHO WE ARE
We are scientists, engineers, researchers, doctors, designers, and business strategists all working together to put the power of data and intelligence to work for you.
Along with data, our experts consult with you on best pathways to identify, target and deploy effective opportunities to reduce risks, costs and liabilities on your life science product innovation whether it is pre-market or post-market.
We partner with organizations to ensure that the overall life-cycle remains as robust as possible to include new and ever-changing processes that will expand the business, market potential and product performance and efficacy. Starting with a gap assessment of your organization, the data harnessed allows us to maximize your potential reach with diversified abilities to reach more than a singular set of the population.
STEP 1 | Gap Assessment
Is your organization looking to expand but not sure where to start? Our subject matter experts do a deep dive analysis into your business and product life-cycle where we identify opportunities that will help accelerate your timelines, identify key resources needed and reveal knowledge gaps that are a threat to your bottom-line.
STEP 2 | Business Intelligence
After we have analyzed how the gaps are impacting your life science business & products, our data-driven team works alongside you to develop a strategic and patient-centered plan that will address the overall business structure & operational needs. Our hands-on team will also help craft a customized roadmap to navigate the rigorous & ever-changing regulatory landscape without compromising the quality of your products.
STEP 3 | Clinical Trials
From determining your patient targeting to developing protocols, we provide a symbiotic approach that will enable your development program. We focus on helping you expand toward a highly diverse clinical population that enables a robust data-centric aggregation so that your product works for everyone.
STEP 4 | Market Access & Expansion
Sales and potential earnings are only one part of the market analysis. Many companies struggle to reach a new audience because they are only looking at one area of data. We help you understand where your potential market entry point is, how to effectively communicate with your audience and actively work with you to develop impactful programs around it.
BRINGING TOMORROW, TODAY
The healthcare industry
It is no coincidence that companies in the life sciences industry have developed specialized needs to address the challenges it faces in the pursuit of not only quality issues and compliance requirements, but patient protection and transparency. It is to address these obstacles that Rubix works to facilitate the implementation of strategies and resources that make them manageable and improve overall industry growth, compliance, and quality.
We are powered by
The first-ever platform to index and collate an entire collection of therapeutic treatment libraries. With its proactive and predictive capabilities, KRONOS is able to predict cancer death rate probability and suggest alternative treatment options.
Rubix LS primary goal is to eradicate rare diseases. We do this through transformative research and development, engineering breakthrough and life-altering products, sourcing world-class talent to support life science companies as well as partnering with like-minded, influential organizations focused on the same goal.
News & Resources
Industry news, company updates and everything in between.
Lawrence Award Program Honors the Achievement LAWRENCE, MA December 17, 2018 -- Rubix LS has been selected for 2018 Best of Lawrence Award in the Research and Product Development category by the Lawrence Award Program. Each year, the Lawrence Award Program identifies...
Rubix LS announces new Phase II milestone data analysis in lead combination product candidate Project Hercules for targeting osteonecrotic (avascular necrosis) disease
Lawrence, MA - Today, Rubix LS announced the success of a critical milestone within the Phase IIa study of Project Hercules. Designed as an implantable combination device with wider applications toward targeting osteopenia, arthrodesis and certain malignancies such...
Anthrax. Ebola. Smallpox. These are just a few of the biological agents that could be weaponized for a bioterrorism attack and unlike a bombing or shooting, these microbial agents can incubate for days or weeks going unnoticed until unrelenting illnesses or deaths...